Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Metrics to compare | A71 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipA71PeersSector | |
---|---|---|---|---|
P/E Ratio | −22.0x | −1.4x | −0.5x | |
PEG Ratio | −0.97 | 0.02 | 0.00 | |
Price/Book | −78.6x | 1.0x | 2.6x | |
Price / LTM Sales | 22.8x | 7.3x | 2.9x | |
Upside (Analyst Target) | - | 197.2% | 66.2% | |
Fair Value Upside | Unlock | 8.6% | 10.3% | Unlock |